Disclosure of Trading In Own Shares for October 2020
Disclosure Of Trading In Own Shares
For October 2020
CLICHY – November 04, 2020
In compliance with general regulation on share buy-backs, SOCIÉTÉ BIC declares below the transactions made on its own shares for October 2020 :
- No transactions for October 2020.
ABOUT BIC
BIC is a world leader in stationery, lighters and shavers. For more than 75 years, the Company has honored the tradition of providing high-quality, affordable products to consumers everywhere. Through this unwavering dedication, BIC has become one of the most recognized brands and is a trademark registered worldwide. Today, BIC products are sold in more than 160 countries around the world and feature iconic brands such as Cello®, Conté®, BIC FlexTM, Lucky Stationery, Made For YOUTM, Soleil®, Tipp-Ex®, Wite-Out® and more. In 2019, BIC Net Sales were 1,949.4 million euros. The Company is listed on “Euronext Paris,” is part of the SBF120 and CAC Mid 60 indexes and is recognized for its commitment to sustainable development and education. It received an A- Leadership score from CDP. For more, visit www.bicworld.com or follow us on LinkedIn, Instagram, Twitter, or YouTube.
CONTACTS
| Sophie Palliez-Capian – VP, Corporate Stakeholder Engagement - [email protected] | |
| Investor Relations Contact: + 33 1 45 19 52 98 | Press Contacts |
| Michèle Ventura [email protected] | Albane de La Tour d’Artaise +33 1 45 19 51 51 [email protected] |
| Isabelle de Segonzac : +33 1 53 70 74 85 [email protected] | |
AGENDA – ALL DATES TO BE CONFIRMED
| Capital Markets Day | November 10, 2020 | Virtual event |
| Full Year 2020 Results | 17 February 2021 | Conference call and webcast |
| First Quarter 2021 results | 28 April 2021 | Conference call and webcast |
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
- Crypto Bull Run Signal? Q3 ETH Staking Hits 43.8M as Remittix Agrees to Remove 300M RTX From Supply
- Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Soleil Securities, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share